Revolution Medicines, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Revolution Medicines, a clinical-stage precision oncology company, reported significantly increased net losses and R&D expenses in Q3 2025 as it aggressively advances its RAS(ON) inhibitor pipeline, securing new funding and regulatory designations.
NASDAQ
Revolution Medicines, a clinical-stage oncology company, reported increased R&D expenses and net losses in Q2 2025, while securing a significant $250 million royalty financing and advancing its key RAS(ON) inhibitor programs with new Breakthrough Therapy Designations.
NASDAQ
Revolution Medicines reports a net loss of $213.4 million for Q1 2025, alongside updates on its RAS(ON) inhibitor clinical programs.
NASDAQ
10-Q: Revolution Medicines Reports Q3 2024 Results, Highlights Progress in RAS(ON) Inhibitor Programs
Revolution Medicines reports its third quarter 2024 financial results, detailing ongoing clinical trials and financial position.
NASDAQ
Revolution Medicines reports a net loss of $249.2 million for the first six months of 2024, while advancing its RAS(ON) inhibitor pipeline.
NASDAQ
Revolution Medicines reports a net loss of $116 million for Q1 2024, while advancing its clinical-stage RAS(ON) inhibitor programs.